- Philip J. Stephens
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- David J. McBride
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Meng-Lay Lin
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Ignacio Varela
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Erin D. Pleasance
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Jared T. Simpson
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Lucy A. Stebbings
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Catherine Leroy
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Sarah Edkins
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Laura J. Mudie
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Chris D. Greenman
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Mingming Jia
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Calli Latimer
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Jon W. Teague
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- King Wai Lau
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- John Burton
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Michael A. Quail
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Harold Swerdlow
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Carol Churcher
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Rachael Natrajan
(Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK)
- Anieta M. Sieuwerts
(Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands)
- John W. M. Martens
(Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands)
- Daniel P. Silver
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA)
- Anita Langerød
(Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway)
- Hege E. G. Russnes
(Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway)
- John A. Foekens
(Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands)
- Jorge S. Reis-Filho
(Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK)
- Laura van ’t Veer
(The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands)
- Andrea L. Richardson
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA)
- Anne-Lise Børresen-Dale
(Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway)
- Peter J. Campbell
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- P. Andrew Futreal
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK)
- Michael R. Stratton
(Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.)